Héctor Matías Melideo

I'm a funny bartender and my hobby is the nephrology 🇦🇷

[Mayo Clinic Nephrology @MayoClinicNeph]

Dr. Fernando Fervenza will be presenting Efficacy and Safety of Obinutuzumab Compared with Tacrolimus in Primary Membranous Nephropathy: Topline Results of the Phase III MAJESTY Trial on June 5th at ERA Congress! #MayoClinicKidney

[Leonardo V. Riella @LVRiella]

Great renal grand rounds @MGBKidneys Ritu Seethapathy discussing rare entity of podocyte infolding glomerulopathy(PIG) after kidney #transplantation in patient w/ lupus. PIG is a morphologic manifestation of chronic podocyte injury &interferon-driven immune dysregulation @AlJurdi

[NDT @NDTsocial]

Management of adult patients with podocytopathies:

an update from the ERA Immunonephrology Working Group

🆓https://t.co/FLKOPFTxFj

@ERAkidney

[Sam Albadri, M.D., M.Sc. @sam_albadri]

🔦Distinguishing IgA nephropathy (IgAN) vs PGNMID (IgA λ) can be tricky. IgAN often shows λ predominance on IF, but λ ≠ monoclonality.
🔬 IgAN: polyclonal (λ > κ, BOTH present, similar distribution)
🔬 PGNMID: monotypic (λ only, κ absent/trace)
Correlate with morphology:
•IgAN → mesangial deposits (EM), mesangial proliferative (LM)
•PGNMID → subendothelial ± subepithelial deposits + MPGN/endocapillary pattern
⚠️ Serum monoclonal IgA λ ≠ PGNMID (can have MGUS + IgAN)
🧠 Bottom line:
λ predominance = physiologic (IgAN)
λ restriction = pathologic (PGNMID)
Always integrate IF + EM + LM + clinical context
📚 Nasr JASN 2009 | Sethi KI 2010 | KDIGO 2021
#RenalPath #Nephrology #MedEd @MayoClinicPath @Renalpathsoc

[AJKD @AJKDonline]

KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

https://t.co/22G7lEXrB4 (FREE)

@ndahl48 @PauAugust @fouadchebib @mariehogan_md @KristenlNowak @terry_watnickmd

[Leonardo V. Riella @LVRiella]

Historic moment in transplant medicine. Tim, our @mgh_transplant xenotransplant patient, who previously received a gene-edited pig kidney and was off dialysis for 9 months, has now received a human kidney. A new chapter in care and hope. https://t.co/Y5TwaknZVr

[Jonathan Chávez @JonathanNefro]

Publica la nueva actualización de las guías EULAR para el manejo de Nefritis lúpica.

13 recomendaciones que va desde el diagnóstico, objetivos y tratamientos

Gratis��🏻

Ann Rheum Dis 2025
https://t.co/Q3UkSMSO7z

[ASN Publications @asnpublications]

In #ASNJASN: Erythroid ACKR1 Deficiency Aggravates Immune-Mediated Kidney Disease. Read more about how selective erythroid ACKR1 deficiency exacerbated disease activity in experimental glomerulonephritis via changes of the myeloid lineage: https://t.co/Z2PhqkKfkd #BasicResearch

[Josep Maria Cruzado @crz_garrit]

Pig lung transplanted into a person in world first https://t.co/9PRgsVP2fg

[Mayo Clinic Nephrology @MayoClinicNeph]

Antigens in membranous nephropathy: discovery and clinical implications

@SethiRenalPath @fervenzafernan1 @NatRevNeph

https://t.co/stVfw24VuW

[S.E.N. Nefrología @SENefrologia]

🙌Trasplante Renal de Donante Vivo #TRDV
👉Ahora puedes acceder a la información más relevante en https://t.co/ZLxRZcucNJ
🙌Gracias a los Grupos de Trabajo de la S.E.N. #ERCA y @SENTRAsplante

[Jonathan Chávez @JonathanNefro]

¿Hipercloremia?

Inicia con la relación de sodio y cloro sérico, <1.4 es la clave. Este algoritmo ayuda a un abordaje sistematizado y preciso

CJASN 2025
DOI: 10.2215/CJN.0000000806

[Emilia Garcia Chiple @nephropath_gc]

📄 INFORME DE BIOPSIA RENAL | Serie 3 de 3
Además del diagnóstico, el informe debe incluir:
– Comentario clínico
– Resumen de datos clínicos
– Descripción macroscópica
– Hallazgos en MO, IF y ME
– Addendum con estudios adicionales
Basado en: Sethi et al. JASN 2015
#nehropatholgy

[Maria Jose Soler @PepaSolerR]

Recién publicado!!! Dx, marcadores, prevención, ¿Cuándo Bx? AKI‼️‼️No te lo pierdas. @Natalia55548118 #GrupotrabajoFracasoRenalAgudo @SENefrologia @senjoven @msalgueira
Documento de consenso para el diagnóstico y tratamiento de la insufici... https://t.co/YRezHrQnOL

[Carlo Alfieri @carlo_alfieri]

🧠 What does “high risk” really mean in organ donation?
From malignancies & infections to ethical dilemmas— today #ESOT2025 explored the evolving definition of the high-risk donor. @ESOTtransplant

#Transplantation #KidneyTransplant #Ethics #LivingDonation

[AJKD @AJKDonline]

Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study

https://t.co/KUwX4mYG4F #OpenAccess

@ELambourg @FuEdouard @C_H_Grant @johnrpetrie @SamiraBell76 #VisualAbstract #CKD

[Ross Prager @ross_prager]

(1/x) Want to master hemodynamics in 2025? 🫀🫁

Here's how to integrate organ level perfusion (including considering hemodynamic coherence) into your resuscitation approach.

A 🧵

[AJKD @AJKDonline]

Counting down the Top Ten #AJKDBlog posts of 2024:

Commentary by Muhammad J. Azam and @kidneyshawar:

5️⃣ Is It Time to Say Goodbye to the Needle? The Future of Kidney Transplant Rejection Diagnosis and Monitoring

https://t.co/5Pm675VwzU (FREE)

@VUMCKidney @Khairallah_P

[Transplantation @TransplantJrnl]

Transplantation published these FREELY downloadable and impactful papers in 2024 that have made a significant contribution to the field and report the latest findings #TXPforALL #Med
https://t.co/vH2PrV1I3M
https://t.co/uBaILefsUU
https://t.co/JLAlA3UbtT
https://t.co/s0S3GTfoZs

[NDT @NDTsocial]

Tailored management strategies for IgA nephropathy based on clinical presentations

https://t.co/YmkqOUFIFf